CLAIMS:

1. An intranasal formulation comprising an effective amount of riluzole or a pharmaceutically acceptable salt, solvate, anomer, enantiomer, hydrate or prodrug thereof, said formulation further comprising an excipient, said intranasal formulation providing an AUC at a dose of 35mg of from 110% to 180% of the AUC of an oral tablet formulation at a dose of 50mg, said AUC being measured at 0.5 hours, 1 hour or 2 hours after administration.

2. The intranasal formulation of claim 1 wherein the formulation has been subject to freeze drying.

3. The intranasal formulation of claim 1 wherein the riluzole comprises a riluzole prodrug.

4. Use of the intranasal formulation of claim 1 in the manufacture of a medicament for the treatment of a neuropsychiatric disorder or symptom.

5. The use of claim 4, wherein the neuropsychiatric disorder is anxiety disorders, mood disorders, neurodegenerative disorders, pain disorders, ALS, cognitive disorders, Huntington's disease, Parkinson's disease, supranuclear palsy, frontotemporal dementia, frontotemporal lobar degeneration, delirium, Alzheimer's disease, mild cognitive impairment, mild cognitive impairment due to Alzheimer's disease, ataxia, hereditary ataxia, depression, mania, attention deficit disorders, drug addiction, dementia, agitation, apathy, anxiety, psychoses, post-traumatic stress disorders, irritability, and disinhibition, learning disorders, memory loss, mental retardation, Rett Syndrome, tinnitus, personality disorders, bipolar disorders, obsessive-compulsive disorders, eating disorders, conduct disorders in DSM-5 and or combinations thereof.

6. The use of claim 4, wherein the neuropsychiatric symptom is anxiety, depression, stress, fatigue, feelings of panic, fear, uneasiness, problems in sleeping, cold or sweaty hands and/or feet, mood liability, mania, impaired concentration or attention, cognitive problems, obsessions, compulsions, repetitive behaviors, aggression, social phobias or impairments, stage fright, shortness of breath, heart palpitations, an inability to be still and calm, dry mouth, numbness or tingling in the hands or feet, nausea, muscle tension, dizziness apathy, elation, disinhibition, irritability, wandering, irritable bowel, belly pain, belly discomfort, diarrhea, change in bowel habits, abdominal bloating, abdominal gas, abdominal bloating, constipation or combinations thereof.

7. The use of claim 4, wherein the effective amount of riluzole for the intranasal formulation to achieve a therapeutic dose is less than that of orally administered riluzole.

8. The use of claim 4, which produces a rapid therapeutic onset of action within about 10 minutes after administration.

9. The use of claim 4 wherein the liver function abnormalities side effects of riluzole are attenuated relative to those which are associated with the orally administered riluzole.

10. The use of claim 4 wherein the intranasal formulation is to be dosed at or below about 50 mg/day.

11. The use of claim 4 wherein the intranasal formulation is to be dosed at or below about 35 mg/day.